Auxo Firm Directory · Independent Research Profile

Quadria Capital

Quadria Capital invests in large, growth-oriented, scalable healthcare companies across South and Southeast Asia. Its stated approach includes healthcare-specific due diligence, value-creation planning, operating support, and both significant minority and majority investments.

Key takeaway

Quadria Capital is a healthcare-focused private equity firm that invests across South and Southeast Asia.

It targets scalable businesses with differentiated market positions, strong management teams, proven business models, sustainable cash flows, and potential for operational improvement.[1][2][3][4][5][11]

What does Quadria Capital invest in?

Quadria Capital is an independent healthcare-focused private equity firm investing in healthcare businesses across South and Southeast Asia. The firm publicly describes an approach that combines healthcare investment origination, healthcare-specific due diligence, value-creation planning, operating support, portfolio-company partnerships, and exit planning.[1][2]

Quadria states that it invests in large, growth-oriented, scalable healthcare companies with clear market differentiation, strong management teams, and potential to become market leaders. Its approach is described as active and fundamentals-driven, with attention to proven business models, sustainable cash flows, operational-improvement potential, management strength, and affordable-quality-healthcare missions.[2][3]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Published size criteriaPublicly stated range
Lower published point$1.07BILLION
Upper published point$800MILLION

Published criteria: Fund III closed with US$1.07 billion in total commitments, exceeding its original US$800 million target. The fund is intended to build a diversified portfolio of approximately 10 market-leading companies using significant minority and majority stakes.[4]

What should a business owner evaluate before considering a transaction with Quadria Capital?

For an owner evaluating a sale or capital partnership, Quadria’s public materials establish a healthcare-specialist investment approach, regional coverage across South and Southeast Asia, active portfolio support, and experience with both minority and majority positions. The proposed ownership percentage, governance rights, capital vehicle, available follow-on capital, expected investment horizon, exit strategy, assigned operating resources, management incentives, rollover equity expectations, and reserved matters should be confirmed for the specific transaction.[1][2][4][6][7][8][9][10]

01

What ownership percentage and governance rights would Quadria seek

Quadria’s Fund III is intended to use significant minority and majority stakes, and its public transaction record includes both minority investments and a 100% take-private. The proposed ownership and governance structure should therefore be established for the specific transaction.[4][6][8][9][10]
02

Which fund or co-investment vehicle would provide the capital, and how much remaining capacity is available

Quadria states that Fund III closed with US$1.07 billion in total commitments and that targeted LP co-investments may be used. The specific capital source and available capacity for the proposed investment are not established by the cited claims.[4]
03

What is the expected investment horizon and exit strategy for the specific company

Quadria publicly describes exit planning and identifies strategic sales and IPOs as exit routes, while its public materials also document a partial exit through the NephroPlus IPO. The expected horizon and exit strategy for a particular company should be confirmed directly.[2][7]

What companies does Quadria Capital target?

The firm’s stated criteria include scalability, clear market differentiation, strong management teams, proven business models, sustainable cash flows, and potential for operational improvement. Quadria also identifies affordable-quality-healthcare missions as an evaluation consideration.[2][3]

Quadria’s stated focus sectors are Healthcare Delivery, Life Sciences, Medical Technology, and Associated Healthcare Services. Its official portfolio classifications include Healthcare Delivery, Life Sciences, Medical Devices, and Associated Healthcare Services.[1][5]

Quadria invests in high-growth healthcare markets within South and Southeast Asia. Its official materials specifically identify India, Vietnam, Indonesia, Malaysia, and Singapore.[1][4]

The sources cited for this profile establish Quadria’s investment in scalable healthcare companies and its use of significant minority and majority stakes, but they do not establish a separate platform-versus-add-on acquisition policy. An owner should clarify whether a proposed investment would serve as a standalone company investment, a platform investment, or part of a broader acquisition strategy.[3][4]

Quadria’s official portfolio identifies companies across Healthcare Delivery, Life Sciences, Medical Devices, and Associated Healthcare Services. Named examples include NephroPlus, Maxivision, Straits Orthopaedics, MediBuddy, Encube Ethicals, and Nobel Hygiene.[5]

Quadria and co-investors completed the take-private of Apex Healthcare Berhad on February 24, 2026, at an implied market capitalization of approximately MYR 1.9 billion (US$470 million), with the consortium acquiring 100% ownership.

Quadria announced a partial exit of NephroPlus through its IPO on December 17, 2025, while retaining approximately 30% fully diluted ownership. It also announced a US$100 million minority investment in Aragen Life Sciences on January 13, 2025, at an approximate valuation of US$1.4 billion; an INR 850 crore significant-minority investment in NephroPlus on May 6, 2024; and an investment of up to US$155 million in Maxivision Eye Hospital on July 12, 2023.[6][7][8][9][10]

What is not clear from Quadria Capital's public investment criteria?

Quadria’s official portfolio page lists portfolio companies and sector classifications but does not publish transaction values, ownership percentages, or acquisition dates for all listed entries.

Quadria’s official Terms page identifies Quadria Capital Investment Management Pte Ltd as governed by the Monetary Authority of Singapore but does not specify the precise MAS licence, exemption, or registration category.[5][11]

Questions to ask when evaluating Quadria Capital as a buyer or investment partner

What ownership percentage and governance rights would Quadria seek?
Quadria’s Fund III is intended to use significant minority and majority stakes, and its public transaction record includes both minority investments and a 100% take-private. The proposed ownership and governance structure should therefore be established for the specific transaction.[4][6][8][9][10]
Which fund or co-investment vehicle would provide the capital, and how much remaining capacity is available?
Quadria states that Fund III closed with US$1.07 billion in total commitments and that targeted LP co-investments may be used. The specific capital source and available capacity for the proposed investment are not established by the cited claims.[4]
What is the expected investment horizon and exit strategy for the specific company?
Quadria publicly describes exit planning and identifies strategic sales and IPOs as exit routes, while its public materials also document a partial exit through the NephroPlus IPO. The expected horizon and exit strategy for a particular company should be confirmed directly.[2][7]
Which operating partners and regional healthcare relationships would be assigned to the company?
Quadria describes operating support and portfolio-company partnerships as part of its approach. The personnel and resources assigned to an individual investment are not identified in the cited claims.[2]
How does Quadria evaluate clinical quality, regulatory compliance, patient outcomes, and ESG impact?
Quadria states that it applies healthcare-specific due diligence and considers affordable-quality-healthcare missions. The specific evaluation framework for clinical, regulatory, patient-outcome, and ESG matters should be clarified for the company under consideration.[2]
What follow-on acquisition or expansion capital could be available?
Quadria describes investment in scalable healthcare companies and a diversified Fund III portfolio using significant minority and majority stakes. The amount and structure of any follow-on capital for a particular company are not established by the cited claims.[3][4]
Which transaction terms, rollover equity expectations, management incentives, and reserved matters would apply?
Quadria’s public materials establish that it uses both minority and majority investments, but they do not specify the transaction terms or management arrangements for an individual investment. Those terms should be addressed in company-specific discussions.[4][6][8][9][10]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Investment strategy
  4. Geography / market coverage
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. Transaction / portfolio evidence
  11. Structure / regulatory context
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.